Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Other Operating Expenses (2022 - 2025)

Historic Other Operating Expenses for Coeptis Therapeutics Holdings (COEPW) over the last 4 years, with Q3 2025 value amounting to $1.9 million.

  • Coeptis Therapeutics Holdings' Other Operating Expenses rose 6257.68% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 4884.85%. This contributed to the annual value of $6.8 million for FY2024, which is 5087.82% down from last year.
  • Per Coeptis Therapeutics Holdings' latest filing, its Other Operating Expenses stood at $1.9 million for Q3 2025, which was up 6257.68% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, Coeptis Therapeutics Holdings' Other Operating Expenses registered a high of $6.1 million during Q1 2023, and its lowest value of -$174648.0 during Q4 2022.
  • For the 4-year period, Coeptis Therapeutics Holdings' Other Operating Expenses averaged around $1.9 million, with its median value being $1.9 million (2024).
  • Within the past 5 years, the most significant YoY rise in Coeptis Therapeutics Holdings' Other Operating Expenses was 500121.34% (2024), while the steepest drop was 6758.55% (2024).
  • Over the past 4 years, Coeptis Therapeutics Holdings' Other Operating Expenses (Quarter) stood at -$174648.0 in 2022, then skyrocketed by 1253.26% to $2.0 million in 2023, then fell by 27.64% to $1.5 million in 2024, then rose by 29.06% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $3.9 million for Q2 2025, and $3.7 million during Q1 2025.